Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

8.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anika Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. – ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Nutex, Anika, Fluor, and Inspire Medical and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Anika (ANIK) Q2 Revenue Beats by 4%
Via The Motley Fool
Topics Economy
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Reports Mixed Q2 2025 Results with Revenue Beat but EPS Miss, Shares Drop 9% in Pre-Market
Anika Therapeutics reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. Shares fell 9% amid Hyalofast trial concerns despite strong regenerative solutions growth. 
Via Chartmill
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For May 9, 2025
 
Via Benzinga
A Glimpse of Anika Therapeutics's Earnings Potential
 
Via Benzinga
Anika to Participate in the Sidoti Virtual Investor Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.